MedTrace Logo

Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07787273 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-08-26

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.

Conditions

  • Locally Advanced Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • Camrelizumab

Interventions

DRUG

Interferon-γ

1,000,000 IU administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.

DRUG

Camrelizumab

200 mg administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.

Sponsors & Collaborators

  • Hefei Cancer Hospital of the Chinese Academy of Sciences

    lead NETWORK

Principal Investigators

  • Hongzhi Wang · Hefei Cancer Hospital, Chinese Academy of Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-20
Primary Completion
2028-03-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07787273 on ClinicalTrials.gov